• Shreelakshmidevi Singaravelu
• Jaikumar S

Lenalidomide is an angiogenesis inhibitor with immunomodulatory properties and possess lesser toxicity when compared with Thalidomide and other teratogenic agents. The histopathological study reveals ductal carcinoma induced by 7.12DMBA and reduction in malignant cells in Lenalidomide and Docetaxel treated group. Breast cancer management with Lenalidomide will have less teratogenicity on par with Thalidomide. Along with its anti-angiogenic property Lenalidomide is also a potent antioxidant and Immunomodulatory agent which adepts it for Breast cancer treatment.

"ANTI-TUMOR EFFECT OF LENALIDOMIDE IN EXPERIMENTALLY INDUCED BREAST CANCER ON FEMALE WISTAR RATS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 5, page no.492-497, May-2019, Available :http://www.jetir.org/papers/JETIRCJ06106.pdf

"ANTI-TUMOR EFFECT OF LENALIDOMIDE IN EXPERIMENTALLY INDUCED BREAST CANCER ON FEMALE WISTAR RATS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 5, page no. pp492-497, May-2019, Available at : http://www.jetir.org/papers/JETIRCJ06106.pdf